Moderna Announces That Its MRNA-1403 Norovirus Vaccine Candidate Did Not Meet Statistical Criteria For Early Success At Phase 3 Interim Analysis; Now Preparing To Enroll An Additional Cohort

Observed price moves

• MRNA+2.20%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.